中国雪蛤酶解液预防去卵巢大鼠骨质疏松

背景：以往研究发现雪蛤具有预防绝经后相关疾病的作用，但是否具有预防绝经后骨质疏松的功效有待于深入研究。 目的：验证雪蛤酶解液对去卵巢大鼠骨质疏松的预防作用。 方法：健康成年Wistar大鼠72只，按随机数字表法分为6组，每组12只。假手术组大鼠不切除卵巢仅切除卵巢周围部分脂肪，其余各组均切除卵巢造成骨质疏松模型。于造模后第7天开始，各组等容灌胃，连续12周。假手术组和模型组每日灌胃等量蒸馏水；普雷马林组每日灌胃387.8 g/L普雷马林(结合雌激素片)悬浮液6. 67 g/(kg•d)；67.0，26.8，13.4 g/(kg•d) 蛤士蟆酶解液组每日分别按相应剂量灌胃。每个月测定食物利用率；实验12周末时，处死大鼠后取子宫，测定子宫质量；取左、右侧股骨和腰椎骨，双能X射线骨密度仪测定骨密度；电感偶合等离子体直读光谱仪测定骨钙、磷含量；脱脂、灰化后测定骨干质量、灰质量。 结果与结论：在4组干预组中，67.0 g/(kg•d)蛤士蟆酶解液组和普雷马林组的食物利用率最低(P < 0.05)；在各切卵巢组中，普雷马林组的子宫质量最重(P < 0.05)；26.8 g/(kg•d) 蛤士蟆酶解液和普雷马林可以延缓切卵巢大鼠股骨骨密度的下降(P < 0.05)；67.0，26.8，13.4 g/(kg•d)蛤士蟆酶解液组骨钙和骨磷与模型组比较均有明显提升(P < 0.05)，与普雷马林组差异无显著性意义(P > 0.05)。提示雪蛤酶解液对去卵巢大鼠的骨质疏松具有预防作用，其疗效与结合雌激素片相当，且对子宫增生的不良反应低于结合雌激素片。

Ovidutus Ranae enzymatic hydrolyzate prevents osteoporosis in ovariectomized rats

BACKGROUND: Previous studies showed that Oviductus Ranae plays a role in some symptoms of menopause. But its effect on prevention of osteoporosis required further investigation. OBJECTIVE: To evaluate the effect of Oviductus Ranae enzymatic hydrolyzate on preventing osteoporosis in ovariectomized (OVX) rats. METHODS: A total of 72 adult and female Wister rats were randomly divided into 6 groups with 12 rats in each group. The osteoporosis model was induced in rats by the OVX with the exception of the sham operation group. The medication commenced from 7 days after operation and lasted continuously for 12 weeks. The rats of sham operation group and the OVX group left were given equal volume of distilled water. Premarin group was perfused with 387.8 g/L Premarin (conjugate estrogens tablets) suspension 6. 67 g/(kg•d); 67.0, 26.8, 13.4 g/(kg•d) Oviductus Ranae enzymatic hydrolyzate groups were treated with corresponding dose of hydrolyzate. Food utilization rate was evaluated at the end of 3 months. All rats were sacrificed at the 12th week. Uterines, bone femur dry mass, bone femur ashes mass were weighed with electric scales; bone mineral density (BMD) was observed under DPX-L model X ray densimeter, bone calcium and bone phosphorus were observed under spectrometer. RESULTS AND CONCLUSION: In the four medication groups, the high dose of Ovidutus Ranae enzymatic hydrolyzate group and the Premarin group had the lowest food utilization rate (P < 0.05). In the five OVX groups, uterins weighed was highest in Premarin group (P < 0.05). Both Premarin and moderate dose of Ovidutus Ranae enzymatic hydrolyzate retarded the bone loss (P < 0.05); the bone calcium and bone phosphorus of the three groups which received Ovidutus Ranae enzymatic hydrolyzate were higher than that of the OVX group (P < 0.05), but did not show any difference to that of the Premarin group (P > 0.05). The Ovidutus Ranae enzymatic hydrolyzate plays an important role in the prevention of postmenopausal osteoporosis as well as Premarin, but it had a lower side-effect in uterine hyperplasia.